Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.44 |
| ▸ | PDE4A | P27815 | 5/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | TPO | P07202 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34461751 | 0.81 | MPO (0.42) | MPOTPOMCL1KMT2A | |
| SCHEMBL562981 | 0.75 | PDE4A (0.70) | PNPADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL562982 | 0.75 | PDE4A (0.70) | PNPADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL562265 | 0.74 | PDE4A (0.64) | PNPADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL561895 | 0.74 | PDE4A (0.64) | PNPADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL561896 | 0.74 | PDE4A (0.64) | PNPADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL9032111 | 0.70 | PNP (1.00) | PNPADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL1461128 | 0.68 | PNP (0.62) | PNPADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL7604273 | 0.65 | ADORA2B (0.72) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4259212 | 0.65 | MPO (0.62) | MPOTPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | WRN, POLR1A, REV1 | PNP 451/4885ADORA2B 734/4885PDE4A 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.